Medindia

X

Bioinformatics Expert Dr. Jiaan Yang Joins Sundia MediTech With Innovative PFSC Technology

Saturday, September 19, 2009 General News J E 4
Advertisement
SHANGHAI, July 6 Sundia MediTech Company, a leadingintegrated pharmaceutical and biotech R&D outsourcing company in Shanghai,China announced today that Sundia has acquired Protein Folding Shape Code(PFSC) technology for doing probe binding site for drug discovery fromMicrotech Nano LLC, a R&D Company in Indianapolis, IN, USA. As a part of thisbusiness deal, Dr. Jiaan Yang, the founder and President of Microtech Nano LLCjoins Sundia as Vice President of Drug Discovery Technology.

Dr. Yang was trained as a physical chemist. In his 26 year professionalcareer in pharmaceutical, biotech and nanotechnology industries in USA, heaccumulated a broad range of experience in bioinformatics with expertise intheoretical chemistry, quantum chemistry, computational chemistry, molecularbiology and computer information technology.

In recent years, Dr. Yang quit his job from Eli Lilly and devoted 3 yearsto research and to develop an innovative method to describe protein complex 3Dstructure, and achieved PFSC, an outstanding success. For a long time, it hasbeen a great challenge to protein chemists and biologists how to obtain acomplete description of protein 3D structure, including the irregular shapesof loops and coils. With his expertise in multiple fields, Dr. Yang appliedmathematics on this biology subject, generated a set of Protein Folding ShapeCode (PFSC) for a complete description of protein's complex 3D structure, anddeveloped computer software to process protein data. The success of PFSC is abig scientific breakthrough in structural biology research.

Sundia's Chairman and CEO Dr. Xiaochuan Wang commented that "theapplication of PFSC technology will bring a great impact to pharmaceuticalresearch and drug discovery." According to her, the PFSC is able toeffectively screen protein 3D structure database, probe new indications,explore potential side effects, and help better understanding drug and diseasemechanisms on a molecular level and quantitative assessment for ligand-bindingsite to assist drug design.

"With PFSC, Sundia can serve our client companies new drug discovery needsmore effectively. Scientists like Dr. Yang, who has a solid scientific skillset, as well as a strong business mindset and entrepreneurial spirit willgreatly enhance our CRO service level," said Dr. Xiaochuan Wang.

Dr. Yang holds a Ph.D. degree in physical chemistry from Louisiana StateUniversity in USA, supervised by Dr. Neil Kestner. He also received a M.S.degree from Theoretical Chemistry Institute, Jilin University in China, withProfessor Tang Aoqing.

About Sundia: Sundia MediTech Company is a leading integratedpharmaceutical contract research organization (CRO) company based in Shanghai,China, to provide R&D outsourcing services to biotech and pharmaceuticalcompanies worldwide, ranging from early hit screening, biological service,lead optimization, DMPK, candidate preclinical development, formulationdevelopment, API manufacture, and regulatory submission. For more information,please visit http://www.sundia.com .

SOURCE Sundia MediTech Company
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Multiple Advantages to Boost Deployment of Wireles...
S
ATS Medical Announces FDA Clearance and First Impl...